{
    "clinical_study": {
        "@rank": "146280", 
        "acronym": "Evered", 
        "arm_group": [
            {
                "arm_group_label": "ERL & TAC", 
                "arm_group_type": "Experimental", 
                "description": "Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw"
            }, 
            {
                "arm_group_label": "ERL & TAC --> MMF/MPA", 
                "arm_group_type": "Experimental", 
                "description": "Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid"
            }, 
            {
                "arm_group_label": "Standard dose TAC + MMF/MPA", 
                "arm_group_type": "Experimental", 
                "description": "Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this pilot study is to evaluate concentration-controlled everolimus with low\n      dose tacrolimus compared to early conversion to CNI-free regimen and MMF/MPA with standard\n      dose tacrolimus in de novo renal transplant recipients of ECD/DCD kidneys.  Given tacrolimus\n      and MMF/MPA is a widely prescribed immunosuppressive regimen in the United States,\n      comparisons of tacrolimus and MMF/MPA regimens to investigational therapies and treatment\n      regimens are needed.  Also, considering the fact that ECD/DCD is a fast growing fraction of\n      donors, evaluation of various regimens' effects on rather delicate ECD/DCD kidneys is\n      necessary."
        }, 
        "brief_title": "A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Delayed Graft Function", 
        "condition_browse": {
            "mesh_term": "Delayed Graft Function"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this pilot study is to evaluate concentration-controlled everolimus with low\n      dose tacrolimus compared to early conversion to CNI-free regimen and MMF/MPA with standard\n      dose tacrolimus in de novo renal transplant recipients of ECD/DCD kidneys.  Given tacrolimus\n      and MMF/MPA is a widely prescribed immunosuppressive regimen in the United States,\n      comparisons of tacrolimus and MMF/MPA regimens to investigational therapies and treatment\n      regimens are needed.  Also, considering the fact that ECD/DCD is a fast growing fraction of\n      donors, evaluation of various regimens' effects on rather delicate ECD/DCD kidneys is\n      necessary.\n\n      The primary objective of this study is to evaluate concentration-controlled everolimus and\n      low dose tacrolimus compared to MMF/MPA with standard dose tacrolimus at 24 months\n      post-transplant with respect to the composite efficacy failure rates (treated biopsy proven\n      acute rejection episodes (BPAR), graft loss, death, loss to follow-up) in de novo renal\n      transplant recipients.\n\n      The key secondary objective is to compare renal function of the everolimus treatment arms to\n      the MMF/MPA treatment arm at 12 and 24 months post-transplantation.  Renal function will be\n      measured by the calculated glomerular filtration rate (GFR), using the MDRD (Modification of\n      Diet in Renal Disease) formula (20)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male or female recipients 18-65 years of age undergoing primary or secondary kidney\n        transplantation\n\n        Recipients of primary or secondary cadaveric, ECD/DCD kidney (defined as follows)\n\n        Donor whose heart has irreversibly stopped beating, previously referred to as\n        non-heart-beating or asystolic donation\n\n        Brain-dead donor > 60 years old\n\n        Donor aged 50-59 years old with two of the following criteria:\n\n        History of hypertension\n\n        Terminal serum creatinine \u2265 1.5 mg/dL\n\n        Death resulting from cerebrovascular accident\n\n        Patients who have given written informed consent to participate in the study\n\n        Exclusion Criteria:\n\n        Cold ischemic time (CIT) > 30 hours\n\n        Patients who are ABO incompatible transplants, or T, or B cell crossmatch positive\n        transplant\n\n        Patients with a known hypersensitivity to any of the study drugs or to drugs of similar\n        chemical class\n\n        Non-controlled DCD\n\n        Donor age >70\n\n        Patients with BMI >32 at baseline before surgery\n\n        Pregnant or lactating females\n\n        Females of childbearing potential unwilling to use an effective means of contraception or\n        are planning to become pregnant\n\n        Patients with platelet count <100,000/mm3 at the evaluation before randomization.\n\n        Patients with an absolute neutrophil count of < 1,500/mm\u00b3 at baseline before surgery or\n        white blood cell count of < 4,500/mm\u00b3\n\n        Patients who are recipients of multiple solid organ transplants\n\n        Patients who have severe hypercholesterolemia (>350 mg/dL; >9 mmol/L) or\n        hypertriglyceridemia (>500 mg/dL; >5.6 mmol/L). Patients with controlled hyperlipidemia\n        are acceptable\n\n        Patients who have an abnormal liver profile such as ALT, AST, Alk Phos or total bilirubin\n        >3 times the upper normal limit\n\n        Patients who are treated with drugs that are strong inducers or inhibitors of cytochrome\n        P450 3A4, such as terfenadine, astemizole, cisapride, erythromycin, azithromycin,\n        itraconazole, rifampin or lovastatin\n\n        Patients who received an investigational drug or who have been treated with a non-protocol\n        immunosuppressive drug or treatment within 30 days or 5 half-lives prior to randomization\n\n        Patients with a history of malignancy of any organ system, treated or untreated, within\n        the past 2 years whether or not there is evidence of local recurrence or metastases, with\n        the exception of localized basal cell carcinoma of the skin\n\n        Patients who are HIV-positive or Hepatitis C (PCR+ only) or B surface antigen positive\n\n        Recipients of organs from donors who test positive for Hepatitis B surface antigen or\n        Hepatitis C (PCR+ only) are excluded\n\n        Patients with a history of severe diarrhea, active peptic ulcer disease, or uncontrolled\n        diabetes mellitus (Hgb A1c <7.0 %) at baseline\n\n        Patients who have any surgical or medical condition, which in the opinion of the\n        investigator, might significantly alter the absorption, distribution, metabolism and\n        excretion of study medication, and/or the presence of severe diarrhea or active peptic\n        ulcer\n\n        Patients who have cardiac failure (e.g. resting dyspnea, symptoms with less than ordinary\n        activity, marked limitation of activity) at time of screening or any other severe cardiac\n        disease as determined by the investigator\n\n        Patients with abnormal physical or laboratory findings of clinical significance within 3\n        months of randomization which would interfere with the objectives of the study\n\n        Patients with any history of coagulopathy or medical condition requiring long-term\n        anticoagulation therapy after transplantation  (Low dose aspirin treatment is allowed)\n\n        Patients with known history of focal segmental glomeruloscrelosis\n\n        Presence of psychiatric illness (i.e., schizophrenia, bipolar, major depression) that, in\n        the opinion of the investigator, would interfere with study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878786", 
            "org_study_id": "IIRPCRAD001AUS183T"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ERL & TAC", 
                    "ERL & TAC --> MMF/MPA"
                ], 
                "description": "One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus.  Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile.  The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing.  In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "Zortress"
            }, 
            {
                "arm_group_label": [
                    "ERL & TAC", 
                    "ERL & TAC --> MMF/MPA", 
                    "Standard dose TAC + MMF/MPA"
                ], 
                "description": "One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus.  Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile.  The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing.  In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "Prograf"
            }, 
            {
                "arm_group_label": [
                    "ERL & TAC --> MMF/MPA", 
                    "Standard dose TAC + MMF/MPA"
                ], 
                "description": "Control Drug", 
                "intervention_name": "Mycophenolate mofetil (MMF/MPA)", 
                "intervention_type": "Drug", 
                "other_name": "CellCept"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolate mofetil", 
                "Everolimus", 
                "Sirolimus", 
                "Tacrolimus", 
                "Mycophenolic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "kidney failure", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20007"
                }, 
                "name": "Georgetown University Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Pilot Study Comparing the Safety and Efficacy of Zortress (Everolimus) With Low Dose Tacrolimus to Early Conversion to Calcineulin Inhibitor-Free Regimen and Mycophenolic Acid With Standard Dose Tacrolimus in Recipients of ECD/DCD Kidneys", 
        "other_outcome": {
            "measure": "Incidence of Cytomegalovirus (CMV) (viremia or viruria)", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "overall_official": {
            "affiliation": "Georgetown University Hospital", 
            "last_name": "Matthew Cooper", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to evaluate concentration-controlled everolimus and low dose tacrolimus compared to MMF/MPA with standard dose tacrolimus at 24 months  post-transplant with respect to the composite efficacy failure rates (treated biopsy proven acute rejection episodes (BPAR), graft loss, death, loss to follow-up) in de novo renal transplant recipients.", 
            "measure": "Evaluate concentration-controlled Everolimus and low dose Tacrolimus compared to MMF/MPA with standard dose tacrolimus at 24 months", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878786"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Georgetown University Medical Center", 
            "investigator_full_name": "Matthew Cooper", 
            "investigator_title": "Dr. Matthew Cooper", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "The key secondary objective is to compare renal function of the everolimus treatment arms to the MMF/MPA treatment arm at 12 and 24 months post-transplantation.  Renal function will be measured by the calculated glomerular filtration rate (GFR), using the MDRD (Modification of Diet in Renal Disease) formula (20).", 
            "measure": "Compare renal function of the everolimus treatment arms to the MMF/MPA treatment arm at 12 and 24 months post-transplantation", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "source": "Georgetown University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Matthew Cooper", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}